Come and join us for the 12th edition of BioFIT, December 12th and 13th 2023 | In-person, Marseille (France) December 15th 2023 | Online meetings.
With the highest attending rate of TTOs, research institutes and academia together with big pharma, emerging and small biotech, diagnostic companies, pre-seed / seed / Series A investors, BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations, early-stage innovation deals and pre-seed, seed and Series A investment in the field of Life Sciences.
BioRN is supporting the event as a Partner and we are glad to offer to our members 15% discount on 'regular price' until October 9th to attend the conference. Use the discount code: BF23_BIORN_2212.
Annalisa and the BioRN Team
KEY FIGURES:
More than 1000 participants from 35+ countries
80 exhibitors
60+ high-level international speakers
40 innovation projects selected to pitch
More than 3,200 meetings schedules with the partnering systems
TTOs & ACADEMIA: Ascenion | BioAster | BioInnovation Institute | Cancer Research UK | EMBLEM Technology Transfer | Fraunhofer Institute for Cell Therapy and Immunology | IFOM | Imperial College London | INRAE Transfert | IOCB Tech | JUNIA | SATT Network | UCL Innovation and Enterprise | University of Birmingham | University of Oxford…
(PRE-SEED, SEED, SERIES A) +ND Capital | AdBio Partners | BioGeneration Ventures | Cambridge Innovation Capital | Capital Grand Est | EQT Life Sciences | eureKARE | European Investment Fund | Forbion | Fund+ | Health Innovation Capital | High-Tech Gründerfonds | INKEF Capital | Jeito | Novo Holdings A/S | Novo Seeds | Sofinnova Partners | SV Health investors | Syncona | Theodorus Investment Funds | TVM Capital Life Science | V-Bio Ventures...
Please check out the different participants’ lists of the previous editions, as well as the list of last year’s edition >>here<<.
DOWNLOAD THE PROGRAMME: Brochure 2023
Please feel free to widely share this document with your colleagues, network, partners…
You are currently viewing a placeholder content from Mailchimp. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
